London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: biffa, 15 Jun 2024 10:26
Last post: biffa, 15 Jun 2024 10:26
I can only see a steady climb from here as the penny profit brigade finally fook off and leave us to it.
Decent questions from Colin,Neil,Graham and Simon yesterday (and me).
At last we have an up to date line in the sand valuation of £40M that we can add/subtract to as news comes in.
If they don't get the SP up we might be on the receiving end of a bid ourselves!
Started: biffa, 15 Jun 2024 10:24
Last post: biffa, 15 Jun 2024 10:24
Mr Kight, HNW individual has just disclosed over 3%.
Holds 8% of Tekcapital (TEK) His holding worth £2M. TEK invests in spinning out university IP.
Let's hope he sees more value here and continues to add.
Started: biffa, 15 Jun 2024 10:23
Last post: biffa, 15 Jun 2024 10:23
One of our Martlet Investments. £29M!
Echion raises £29 million in Series B investment round
June 14, 2024
Series B fundraise of £29 million led by Volta Energy Technologies with CBMM, BGF and Cambridge Enterprise Ventures
The world’s leading developer of niobium-based, fast-charging battery materials, Echion Technologies, has successfully completed its Series B funding round, raising £29 million in investment capital. The round was led by specialist battery and energy storage technology investor Volta Energy Technologies (Volta), with participation from existing investors CBMM, BGF, and Cambridge Enterprise Ventures.
The investment will enable Echion to execute its go-to-market strategy to see its innovative niobium-based XNO® anode material utilised in real world applications, at volume. Echion is Volta’s first investment into a European headquartered company and having Volta as the lead Series B investor highlights Echion as a rising British battery technology business within the crucial global energy storage industry.
Echion’s longstanding partnership with the world’s leading producer of niobium, CBMM, will see the opening of a 2,000 tonne per year XNO® manufacturing facility this year. This provides Echion with the manufacturing capacity to satisfy the large and growing demand for XNO® across its global customer base comprised of major cell manufacturers and original equipment manufacturers (OEMs).
Started: biffa, 15 Jun 2024 10:21
Last post: biffa, 15 Jun 2024 10:21
Great results and a pretty good presentation that answered most of the questions.
3 out of 4 on the wish list so not to bad.
Decent involvement from a number of people.
Panmure note on it's way which would be a first.
£35.6M plus £4M since year end so £40M vs £15M.
No reason for this not to steadily move higher as news flow and investor interest increases.
Started: Troajan, 13 Jun 2024 11:39
Last post: mornington-oz, 14 Jun 2024 07:22
RNS OUT
Started: biffa, 13 Jun 2024 07:59
Last post: philg65, 13 Jun 2024 09:28
I agree but the market thinks differently. I believe that they're expecting more concrete news for Glycotest.
A positive set of results with more to come.
Started: biffa, 8 Jun 2024 10:06
Last post: baf3, 12 Jun 2024 20:30
It does nothing because the UK marlet is investment market is weak and uk investors are littered with traders that can't add up.
Emv and Netscientific are doing a fantastic job raising sufficient capital to allow businesses to grow from acorns to large trees. They will exit some of these in due course and every one will then realise what they missed out on.
Results day tomorrow which will highlight how undervalued we are. Not expecting markets to get it as investors would sooner put money abroad in companies valued at 100's times sales because some push this as a good idea whereas investing at a third of NAV is a better investment all day long in my opinion
The whole problem is its all totally illiquid save PDBS which is on the floor at $2.7.
Continual funding here and there does nothing. They need to have some healthy crystallisations for even a modest rise.
Loads of news coming out from PointGrab so worth keeping an eye on.
New website and sales team doing quite well.
Some excellent news out today.
PDSB continues to show top of the class data. SP is a joke.
Really positive proactive interview out for DeepTech. Direct 21% plus 30% GUA.
Two sites being announced over the next few months where our tech has been licensed to build. Already at the revenue stage.
Let's hope they focus on the important bits tomorrow.
Massive discount to NAV and what they are going to do about it.
Share buy back.
Director/NED buying.
Panmure note.
Portfolio update.
Should do for starters.
Started: Troajan, 12 Jun 2024 09:38
Last post: Troajan, 12 Jun 2024 09:38
Started: biffa, 8 Jun 2024 09:42
Last post: biffa, 8 Jun 2024 09:42
Direct holding 5.4%. CUA 26%.
SageTech Medical secures funding to enhance anaesthetic recycling solution via Innovate UK grant competition win.
Jun 7, 2024
Sagetech Medical, a pioneer in sustainability for both the medical and veterinary sectors, is excited to announce that it has received funding from Innovate UK. This will support the upscaling of its revolutionary process for capturing, recovering, and purifying waste volatile anaesthetic agents. It is not commonly known that these agents, which are potent greenhouse gases, contribute over 3M tonnes of CO2 equivalent emissions across the globe annually.
Launched in January 2023, SageTech’s volatile anaesthetic waste capture technology has already seen commercial success in the UK, and significant interest in overseas markets. There are no existing technologies that can match the performance of SageTech’s processes in terms of efficiency (resource preservation) and carbon savings.
Earlier this month, Innovate UK chose SageTech Medical, in collaboration with the University of Plymouth, as one of the winners of a grant competition which will support the upscaling of their recovery and purification capacity. This upscaled capacity will support rapid and modular expansion across new markets including EU, USA, and beyond. In doing so, SageTech will create a global model for medicines manufacturing that is sustainable and scalable. This initiative not only promises to advance sustainability goals of anaesthetic delivery but also aims to protect the UK from global disruptions and supply chain pressures, such as those experienced during the COVID-19 pandemic.
Steve Wileman, Head of Research at SageTech Medical said: “Our commitment to innovation and sustainability is at the core of everything we do at SageTech Medical. We are very pleased to be working again with our academic partners at the University of Plymouth to deliver this exciting project.”
This project underscores SageTech Medical’s mission to lower carbon emissions in healthcare by tackling an issue that is often overlooked through innovative solutions, and leading the way in sustainable anaesthesia.
EMV CAPITAL LEADS C.£3.4 MILLION FOLLOW-ON INVESTMENT INTO SATCOM LEADER SOFANT
05.06.2024
EMV Capital
Funding to facilitate terminal delivery to key clients in growing SatCom market for commercial and government applications
EMV Capital (“EMVC”), the VC investor specialising in high-growth deep tech companies, is delighted to announce that it has led a c.£3.4m investment round into its portfolio company Sofant Technologies, a leading edge wireless technology company developing next generation phased-array antenna platforms.
The fundraising was led by EMV Capital, syndicated from its cohort of private EIS investors, and joined by Kelvin Capital and Scottish Enterprise. The company is now set to execute its go-to-market strategy, using funds from this investment round to deliver satellite terminals to SatCom operators and their clients in aerospace, defence and security and civilian applications. Sofant has made significant product commercialisation progress, including development contracts with Inmarsat (now part of Viasat), the European Space Agency and a global defence company.
Sofant’s proprietary technology enables operators to enhance their network capabilities and expand service offerings for both commercial and government applications. The company’s proprietary RF MEMS technology facilitates the development of a highly efficient radio platform that directly addresses the most difficult size, weight and power consumption challenges facing future wireless communication systems.
Dr Ilian Iliev, Managing Director of EMV Capital and Sofant Board member, commented:
“We are pleased with the success of this fundraising for Sofant that comes at a critical value inflection point for the company. In line with our capital-light investment strategy, we worked with management and our co-investors to develop the right funding structure for the company as it accelerates development. It is pleasing to see a UK-born semiconductor company make an impact on the global stage as a key enabler for future wireless networks with a growing number of commercial and government applications. We look forward to continuing our important work with the company.”
David Wither, CEO of Sofant, also commented:
“We continue to see strong and increasing interest in our target markets from both customers and prospective new investors. Sofant will use the proceeds from this investment round to deliver fully integrated SatCom terminals to our lead customers for network trials before the end of this year. This milestone represents a key value inflection point and the culmination of many years of development work. We thank EMV Capital and all our investors for their continued support. We look forward to a transformational year, and anticipate the launch of our first SatCom terminal which promises to transform the SatCom industry.’’
Started: biffa, 5 Jun 2024 08:28
Last post: biffa, 5 Jun 2024 08:28
Must be a RNS stuck in the system.
EMV link out saying Sofant just raised £3.5M.
We are 2% and CUA of 30%
Another blinder of a deal.
Started: biffa, 31 May 2024 08:58
Last post: philg65, 31 May 2024 12:50
If we get good news about Glycotest (bearing in mind that it's 100% owned by NSCI), and the SP hardly moves, then you know that the market is rigged!!!!
Another day, another £2M+ uplift in valuation of a portfolio holding.
No doubt SFA on the SP.
Don't know why they don't take it private at £1.30/ £1.50 and be done with it. After all they own over 30% between them.
As I mentioned last week, Charles, the boss of Glycotest is presenting next week. First time in over 5 years he has said anything public.Hopeful we have one of those promised deals along side it?
Started: biffa, 28 May 2024 08:06
Last post: Agricore, 28 May 2024 20:20
Another decent deal for NSCI.
Wanda on the books as 90% CUA valued at £3.6M. We have no direct holding.
We now have 30% direct holding so worth £1M+ (see above)
£150K upfront fee.
£100K a year management charge. (£8K month)
nice flurry of buys on friday.
the business update said results by the end of may so this week i assume.
pretty ****ed off if we don't get a buy back announcement and a full 30 page note from panmure for starters.
Interesting tweet/X out last night from Netscientific.
Charles Swindell is presenting at the Jefferies Health Care on June 4-6th, talking about Glycotest and ProAxis.
He runs Glycotest and he hasn't said or done anything for at least 5 years.
Is it safe to assume we will have some positive Glycotest news beforehand otherwise he won't have much to say other than talk about 4 years of delays!?
Started: biffa, 15 May 2024 19:20
Last post: biffa, 15 May 2024 19:20
I think the risk/reward is as good as it gets.
Glycotest is valued in the books at £11M and we are finally close to a read out. Could be worth £5M or £50M if the test works and Fosan want full control.
ProAxis worth £8M. since then received another £500K in funding grants. Might go for £10M/£15M with a fair wind.
Downside fully protected but upside is potentially massive.
Started: biffa, 14 May 2024 13:25
Last post: philg65, 14 May 2024 15:09
That's great but as Saigonsally alluded , I'll be in my pine box by the time us shareholders make any decent return on this share!!!!
Need to start seeing some hardcore revenue's and profit on these investments.
NetScientific Q&A: "we're right in the middle of the action of venture capital"
https://youtu.be/6IqUrxEFql4
Much better than yesterdays Proactive interview. a win win for NSCI shareholders.
Started: Troajan, 13 May 2024 11:47
Last post: saigonsally, 13 May 2024 16:19
That's all very well and a great RNS today but it sounds to me like the cherry on the jam on the cream of our scone a very long way down the line. How do we squeeze a little bit more market appreciation out of what we have. We won't all live another 40 years (although maybe thanks to NSCI we shall...?).
Started: biffa, 13 May 2024 14:50
Last post: biffa, 13 May 2024 14:50
ProAxis got another £500K grant on Friday.
More good news today being totally ignored by the wider market.
Perhaps some focus on our own share price before we go chasing other investments?
SP 60p vs NAV £2.00+. Just saying!!
Looking at IP GROUP discount to NAV.
They have gone down the share buy back route which is 100% where NSCI should be looking to close the gap between the 60p SP and the £2.00 NAV.
Why invest money elsewhere when you can effectively buy assets at a 200% discount!
Continued commitment to shareholder returns
- Launched further £20m share buyback fulfilling our commitment to regular cash returns from realisations
- As announced on 18 December 2023, future cash returns are expected to be in the form of share buybacks when the share price discount to NAV exceeds 20%
Started: biffa, 16 Apr 2024 23:21
Last post: saigonsally, 20 Apr 2024 11:36
Totally agree Biffa. The problem for me (and a lot more, I suspect) is that even if the share price doubles I am still under water. And I am 'buttered' if I am going to stick in another penny while the shares are behaving like they do
Still can't quite believe we have only gained 1p on that news.
If they are going to sell the lot this summer for £10M in cash? then I hope they put a share buy back into the mix post results.
About time they started narrowing the discount of the 60p share price to the £2.00 asset value.
Started: biffa, 18 Apr 2024 09:22
Last post: biffa, 18 Apr 2024 09:22
Very bullish EMV First qtr newsletter just out.
Well worth a read.
Started: biffa, 15 Apr 2024 07:55
Last post: baf3, 15 Apr 2024 21:47
Nsci is delivering stunning capital growth as the exit some of these investments I am sure we will see elements of Capital distributions. They gave some heavy hitters in their portfolio insane that you can buy at below a third of NAV
This is a brilliant long term investment. Buy them under 60 and forget them. One day it will cash in one of these stakes for 50 times what it cost
Nsci’s biggest problem is that the only way to really deliver tangible returns for shareholders is via capital growth. That’s only going to come from a huge revaluation of its assets, so that the disconnect between its current mkt cap and its underlying NAV, becomes so huge that there’s no choice but for it to be recognised in an increased share price, or through the sale of one or more of its investments and a return of cash to shareholders as a special dividend, or through a floatation of same with Nsci shareholders being granted shares in a new company at the time of spin out.
It’s just not properly understood by the investor landscape yet, and the mgt team don’t seem that bothered to do anything to really sell NSCI to a wider audience …
Very frustrating
L.
There is only new money of 550k - the rest is conversions so its a tad misleading
Couldn't agree more.
Mr. Market is clearly in need of a double dose of Fluoxitine.
Mark it down on shtt trades and ignore a decent 25k buy.
Modest increase on last years fair value of £41.8M (Dec 22) so lets say £45M or £1.80 a share.
MCap at 60p is £15M
Complete joke.
Start a buy back or make us a decent offer.
Almost all of their investments are finally on the up.